A Global, Open-Label, Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Inhaled LIQ861(Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients
Purpose
Category
Heart, Vascular and Blood
Lungs, Breathing and Bronchial
IRB Number
20190423HU
NCT Number
-
Sponsor
-
Study Contact
Principal Investigator
Rodolfo Estrada Anzueto
Johnnie Jones
210-450-7277
jonesj21@uthscsa.edu
Eligibility
Eligible Ages
Eligible Genders
Accepts Healthy Volunteers
No
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups